Safety and Pharmacokinetic Profile of Ocrelizumab in Pediatric MS Mirrors Adult Population
In new data from the OPERETTA 1 study (NCT04075266), a study of pediatric patients with relapsing-remitting multiple sclerosis (RRMS), ocrelizumab (Ocrevus; Genentech) demonstrated a safety and pharmacokinetic/pharmacodynamic (PK/PD) profile that …